Acute Myeloid Leukemia Post Cytotoxic Therapy

Acute Myeloid Leukemia Post Cytotoxic Therapy — Trials · CancerIndex

Clinical trials

Registered studies

55 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 6%
Top sponsor: National Cancer Institute (NCI)
Termination share: 19.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (6)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00093470	Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission	completed	Phase 3	144	National Cancer Institute (NCI)NIH	3	Jul 14, 2026	clinicaltrials
NCT01307579	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia	completed	Phase 3	517	Children's Oncology GroupNETWORK	3	Mar 30, 2021	clinicaltrials